XtalPi
VC Fund
Cambridge, United States
XtalPi is a pharmaceutical technology company that is reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform. Through its tightly interwoven quantum mechanics, artificial intelligence, and high-performance cloud computing algorithms, the ID4 platform enablespharmaceutical companies to increase their efficiency, accuracy, and success rate at critical stages of drug R&D. By accelerating the pace of drug discovery and development, XtalPi aims to contribute to a healthier society worldwide.Founded in 2014 by a group of quantum physicists at MIT, XtalPi has since grown into an elite team of researchers with multi-disciplinary expertise in physics, chemistry, pharmaceutical R&D, and algorithm design. XtalPi has received much recognition for its cutting-edge technologies, its innovative solutions, and the breadth of potential applications of its offerings across the pharmaceutical value chain, which has allowed it to gain industry approval and establish strategic partnerships with several top international pharmaceutical companies.
- Total investments:
- 28
- Last investment:
- Lead investor:
- 43%
Last updated:
For AI agents: llms.txt
Industries XtalPi invests in
Stages XtalPi invests in
Countries XtalPi invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 6 contacts → | |||
Round size
- Seed
- $1.5M–$15M
- Angel
- $9.2M–$50M
- Series A
- $11M–$30M
Investment Focus
Industry
- Biotechnology 13 (46%)
- Health Care 7 (25%)
- Pharmaceutical 6 (21%)
- Biopharma 5 (18%)
- Medical 4 (14%)
Stage
- Series A 7 (25%)
- Seed 6 (21%)
- Angel 4 (14%)
- Corporate Round 2 (7%)
- Venture - Series Unknown 2 (7%)
Country
- China 12 (43%)
- United States 4 (14%)
- Japan 1 (4%)
- Hong Kong 1 (4%)
- Switzerland 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
William Glauser
Senior Vice President of Business Strategy
|
Senior Vice President of Business Strategy | Total investments: 0 | Find email | |
Jian Ma
Co-Founder and CEO
|
Co-Founder and CEO | Total investments: 0 | Find email | |
Lipeng Lai
Co-Founder
|
Co-Founder | Total investments: 0 | Find email | |
Sarah Trice
COO, Head of US Operations
|
COO, Head of US Operations | Total investments: 0 | Find email | |
Shuhao Wen
Founder
|
Founder | Total investments: 7 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Apex Intelligence develops self-evolving AI models for scientific discovery. | $50M / Angel / Sep 16, 2026 | ||
| Rabbitpre is a big data-driven technology marketing company. | Series E / May 07, 2026 | ||
| Xellar Biosystems is a wet artificial intelligence biotechnology company that provides analysis of drug testing and treatment. | $29M / Series A / Apr 02, 2026 | ||
|
Dingxi Zhichuang
|
Dingxi Zhichuang is an integrated circuit chip developer specializing in the manufacture, design, and services of integrated circuit chips and products, as well as sales and the manufacturing of semiconductor device special equipment. | Angel / Mar 25, 2026 | |
Deepin Technology
|
Deepin Technology is a company that utilizes artificial intelligence, quantum chemistry, and high-throughput experiment technologies to enhance the efficiency and workflow of chemical material innovation. it offers efficient R&D solutions for chemical materials, aiming to solve lab bottlenecks, promote innovative research, and enhance customervalue. | Series A / Mar 04, 2026 | |
| Leman Biotech is a biotech company that is engaged in development of cancer immunotherapies. | $28.8M / Series A / Jan 26, 2026 | ||
| Newdel Biotech offers drug screening services along with biomedical technology development and consulting. | Series A / Jan 21, 2026 | ||
| Signet Therapeutics is a cutting-edge firm that conducts research and development on cancer-targeted drugs using AI and organoid disease models. | $11.5M / Series A / Jan 14, 2026 | ||
| Prenetics is a health sciences company, that is dedicated to consumer and clinical health. Its consumer initiative is led by IM8, a new health and wellness brand, and Europa, one of the top sports distribution companies in the USA. The clinical division is led by Insighta, focused on multi-cancer early detection technologies. This is followed byACT Genomics, which has achieved FDA clearance for genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer DNA tests. Each Prenetics unit impacts health by ‘enhancing life through science’. | $48M / Post-IPO Equity / Oct 27, 2025 | ||
|
PrinMed
|
PrinMed is an innovative company focused on AI infrastructure resources and technology platforms. | Corporate Round / Sep 12, 2025 | |
| See all 28 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does XtalPi invest in?
XtalPi invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series A and Seed stage. Most of the 28 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is XtalPi's check size?
XtalPi typically joins rounds of $1.5M–$15M at Seed, $9.2M–$50M at Angel and $11M–$30M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds XtalPi participates in.
How do I contact XtalPi?
Public channels for XtalPi include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at XtalPi?
The team at XtalPi includes William Glauser (Senior Vice President of Business Strategy), Jian Ma (Co-Founder and CEO) and Lipeng Lai (Co-Founder), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
